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Introduction 
 
The astroglia: morphology and classification 
 
Brain neuroglia comprises non-neuronal cells which support the activity of neurons by 
maintaining homeostasis, producing myelin, and providing support and protection to neuronal 
cells. It can be divided in microglia and macroglia.  
Microglia constitutes about the 20% of the total number of glial cell, and is composed by the 
resident macrophages of the Central Nervous System (CNS), thus constituting its most important 
immune defense (Gehrmann et al., 1995).  
On the other side, macroglia comprises (a) oligodendrocytes, which form the  myelin sheath that 
coats axons in the CNS, (b) ependimoglial cells, which constitute the membrane lining 
the ventricular system of the brain and the spinal cord, and are involved in the production 
of cerebrospinal fluid, and (c) astrocytes (Somjen, 1988; Reichenbach, 1989; Chan et al., 2007).   
Astrocytes are the most numerous cell type in the human brain. They are a sub-type of glial 
cells in the CNS, so called because of the star shaped morphology of the most dominant cell 
types, which bear peculiar arborized processes (Cajal, 1909).  
With routine staining and the light microscope, astrocytes can be viewed  as  pale-staining oval  
to round  or lobate  nuclei with  little or no discernible cytoplasm. Only after metallic 
impregnation, other special stains and immunocytochemical examination can  the process-
bearing nature of these cells be  fully appreciated (Montgomery, 1994). 
Already in the 19
th
 century, it was recognized that astrocytes are a morphologically 
heterogeneous population. They can be divided in two major classes termed protoplasmic and 
fibrous astrocytes. 
Fibrous astrocytes (Fig.1A) have many glial filaments, tend to have regular contours and to 
extend cylindrical branching processes (Schnitzer, 1988; Butt et al., 1994; Butt and Jennings, 
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1994). They are located mainly in white matter, often arranged in rows, and their processes 
usually develop parallel to neurons, and extend multiple finger-like outgrowths in the perinodal 
space of adjacent neurons.  
Protoplasmic astrocytes (Fig. 1B) have fewer glial filaments and are found mainly in gray matter 
(Wolff, 1968; Bushong et al., 2002). They have irregular contours and extend sheet-like 
processes that extend more or less radially from the soma, and appear to fill most of the space 
between the other elements in the neuropil. These projection account for about 50% of the cell’s 
volume, but more than 80% of its surface (Chao et al., 2002). 
 
 
Figura 1: A, fibrous, and B, protoplasmic astrocytes. Adapted from Garcia-Lopez, 2010 (Garcia-Lopez et al., 
2010) 
 
Astrocytes processes are more extensive and branched in mature astrocytes than in younger ones, 
and often envelope the synapses formed by neurons in the CNS, or surround the blood vessels, 
such constituting the blood-brain barrier (Peters and Webster, 1991).  
Immunocytochemical techniques have improved our knowledge about the expression of antigens 
that are, within the CNS, restricted to astrocytes. In addition, some of these markers allow 
distinguishing within the same population between developing, mature ad reactive astrocytes. 
Some of the biochemical markers expressed in mature astroglia are glial fibrillary acidic 
A                                          B 
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protein (GFAP), or Glutamine Synthetase (GS), the high affinity glutamate transporters GLAST 
or GLT-1, the calcium binding protein S100β and tenascin-C (Ghandour et al., 1983). The 
specificity o f GFAP  has been a major breakthrough  in  the  study  of  astrocytes  both in  situ 
and in cell culture, being commonly used to label astrocytes in the CNS to study their 
distribution and morphology, despite the fact that it labels only 15% of the total volume of 
astrocyte (Bushong et al., 2002). 
Table 1 
 
Young astrocytes Mature astrocytes 
A) Electrophysiology 
  
 
Varied Vm Vm=Ek 
 
VDCs VDCs not apparent; linear I-V plot 
 
Varied input resistence Very low input resistence 
 
Varied degree of cell-cell coupling Extensive cell-cell coupling 
B) Markers 
  
 
Aos Aos 
 
- Glutathione transport 
 
- D-serine racemase 
 
EAA transporters EAA transporters 
 
GFAP sometimes GFAP 
 
Nestin - 
 
Vimentin - 
 
GS GS 
 
- S-100β 
C) Morphology 
  
 
Extesive processes More extensive processes and 
arborizations 
 
Ionotropic and metabotropic receptors Mainly metabotropic receptors 
 
Processes contact blood vessels and 
partition the CNS, e.g, glial limitants, or 
parts thereof. 
Also contact mature synapses 
 
Studies investigating the spatial relationships occurring between astrocytes in three-dimensional 
(3D) arrays in situ concluded that astrocyte somata achieve a nonrandom, region-dependent 
degree of spacing between themselves throughout the brain. Furthermore, the processes of each 
astrocyte are extensively intermingled with those of neighboring astrocytes (Dreher et al., 1994; 
Bushong et al., 2002). 
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The contacts occurring between processes were proposed to impart structural integrity to the 
nervous tissue while simultaneously separating somata during development, allowing the 3D 
array of astrocytes to effectively fill the nervous tissue, a phenomenon termed “contact spacing” 
(Tout et al., 1993).       
 
Astrocyte functions and physiology 
 
Astrocytes’ functions range over a wide variety of domains (summarized in Fig. 2). 
CNS compartimentalization 
 
On the structural level, protoplasmic astrocytes shape the microarchitecture of the grey matter by 
dividing it in to relatively independent structural units, creating micro anatomical domains within 
the limits of the ramification of their processes. Individual astrocytes are further integrated into 
astroglial syncytia through gap junctions localized on the peripheral processes. The syncytia can 
also be segregated within defined anatomical structures, such as the individual barrels of the 
somatosensory cortex (Dreher et al., 1994; Bushong et al., 2002). Disruption of astrocyte 
domains has been associated with several mouse models for epilepsy (Seifert et al., 2010) and 
aberrant expression of the astrocyte gap junction protein connexin has also been reported in the 
autistic brain (Fatemi et al., 2008). 
 
Developmental functions  
 
The well-defined spacing of the astrocyte network, with its capacity for intercellular 
communication, has the potential to work as a boundary system for neurons, guiding their search 
for targets during development and ensuring that the activity of mature synapses is appropriately 
contained. Furthermore, in vitro studies have found that astrocytes exert powerful control over 
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the number of CNS synapses. Astrocytes are essential for postsynaptic function, and are required 
for synaptic stability and maintenance (Barker and Ullian, 2008). Recent in vivo studies 
increasingly implicate astrocytes as participants in activity-dependent structural and functional 
synaptic changes throughout the nervous system (Ullian et al., 2004; Eroglu and Barres, 2010).  
 
Homeostasis during adulthood 
 
Glutamate uptake 
 
High affinity glutamate transporters, GLT1 and GLAST1 subtypes, are enriched in astrocytic 
processes, and play the predominant role for glutamate clearance in the adult CNS (Rothstein et 
al., 1996). Glutamate is co-transported with three Na
+
 (or two Na
+
 and one H
+
) in exchange for 
one K
+
 and one OH- (or one HCO3
-
;). The consequence of this stoichiometry is an increase in 
the Na
+
 concentration within the astrocytes, accompanied by an intracellular acidification and 
extracellular alkalization (Robinson and Dowd, 1997). Within the astrocyte, glutamate is 
converted to glutamine through an ATP-requiring reaction catalyzed by the astrocyte-specific 
enzyme glutamine synthetase. Glutamine is subsequently released to the extracellular space to 
fuel neurons and recycled into glutamate for glutamatergic neurotransmission (Loo et al., 1995). 
 
Glutamate signaling 
 
A variety of ionotropic glutamate receptors and metabotropic glutamate (mGlu) receptors have 
been characterized in glia in situ and in cultured astrocytes (Liao and Chen, 2003). 
Astrocytic mGluR are activated during neuronal activity promoting the turnover of ionositol 
triphosphate (IP3), and triggering Ca
2+
 release from intracellular stores independently of 
extracellular Ca
2+  
(Burnashev et al., 1992). 
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Purinergic signaling 
 
Primary glial cells express several members of the P2Y purinergic receptor family (Fam et al., 
2000; Simard et al., 2003). 
Purinergic signaling in astrocytes is involved in interactions with synapses and regulation of 
plasticity and excitability of synaptic networks (Pascual et al., 2005). Release of cytokines (Hide 
et al., 2000) and growth factors (Ciccarelli et al., 1999a).  From astrocytes in response to 
purinergic signaling implicates astrocytes in developmental and injury-related processes (see 
“Astrocytes and NGF” paragraph).  
 
Ion and water homeostasis 
 
The extracellular space of the CNS represents the microenvironment of both neurons and glia. 
Communication of neurons and glial cells is almost exclusively limited to the diffusion of 
neuroactive substances and ions in extracellular space. The role of astrocytes in maintaining 
ionic , pH and and volume homeostasis of the extracellular space is crucial for their modulation 
of synaptic transmission efficacy.  
Ion spatial buffering is based on the high permeability of glial membrane and astrocytic coupling, 
allowing the movement of K+ , Ca2+ and other ions (Coles and Orkand, 1983; Kettenmann et al., 
1983).  
Homeostasis of extracellular pH is regulated by coordinated expression of alkaline membrane 
transporters in neurons and of acid extruders in the glial membrane (Jendelova and Sykova, 
1991). 
In addition, centrally released neuropeptides such as vasopressin (AVP), atriopeptin (ANP), 
angiotensinogen (AGT) and angiotensin (Ang) II appear to regulate fluid and ionic environment 
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and cell volume in the CNS, possibly via intrinsic osmoregulation of glial cells (Simard and 
Nedergaard, 2004). 
 
Ca2+ signaling  
 
Astrocytic Ca
2+
 signaling is expressed as oscillations in cytosolic Ca
2+
 concentrations ([Ca
2+
]i) 
and as slowly propagating waves of [Ca
2+
]. Astrocytes display regular oscillations when acti-
vated by various stimuli including hormones (Berridge, 1994; Smith, 1994). Astrocytes also ac-
tively propagate Ca2
+
 waves. Mechanical stimulation of single astrocytes resulted in expanding 
waves of [Ca2
+
] increments, which engaged 20–100 neighboring astrocytes in culture (Smith, 
1994). They can modulate the Ca
2+
 level, and thereby the firing pattern, of neurons in their sur-
roundings. In turn, neurons can trigger astrocytic Ca
2+
 signaling by releasing glutamate. 
 
Cerebrovascular regulation and Blood Brain Barrier control 
 
Astrocytes send processes to synapses (Chao et al., 2002; Volterra et al., 2002) and blood vessels 
(Reichenbach, 1989), and thus are an integral component of the neurovascular unit.  
Astrocytes has been recently shown to be essential participants in the control of cerebral blood 
flow (CBF) through the control of  cerebral vessel diameter. As stated above, astrocytes respond 
to glutamate with an increase in intracellular Ca
2+ 
through the activation of mGLURs 
 
(Burnashev et al., 1992). The application of mGLUR agonists triggers the release of diffusible 
factors that then act on vascular smooth muscle cells to cause dilation of arterioles (Zonta et al., 
2003b). Among this factors,   arachidonic acid metabolite lead to a localized increase in calcium 
at astrocyte end-feet, which results in dilation of nearby arterioles (Zonta et al., 2003a).  
A second function of astrocytes in the regulation of cerebral vasculature is the participation to 
the formation of the the blood-brain barrier (BBB). The BBB  is a metabolic diffusion barrier which 
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plays a role of “check point” to regulate influx of most compounds from blood to brain. The BBB consists 
of endothelial cells, pericytes with smooth muscle-like properties, and astroglial processes that ensheath 
more than 95% of the abluminal blood vessel surface (Zlokovic, 2008).  Although the impact of 
astrocytes in the maintenance of the BBB is largely unidentified, it can be presumed that a constant 
astrocytic influence is needed to maintain the BBB. A physiological role could be met by the lactate 
shuttle hypothesis (Magistretti et al., 1994), control of ingress of compounds such as glucose and 
aminoacid or egress of waste metabolites (Pellerin and Magistretti, 2004), or control of the concentration 
of K+ and blood flow.  
 
Figure 2. Summary of astrocyte functions. Adapted from Maragakis and Rothstein, 2006 
Glial Fibrillary Acidic Protein (GFAP) 
 
GFAP is a 8-9 nm intermediate filament (IF) protein preeminently expressed in astrocytes. 
First described in 1971 (Eng et al., 1971), it is a type III IF protein closely related to its non-
epithelial family members, vimentin, desmin, and peripherin, which are all involved in the 
structure and function of the cell cytoskeleton.  
Initially, GFAP was purified from large Multiple Sclerosis plaques consisting primarily of 
fibrous astrocytes and demyelinated axons (Eng et al., 1971). The cloned mouse gene and the 
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cloned human gene were subsequently presented, respectively in 1984 (Lewis et al., 1984) and 
1989 (Reeves et al., 1989). 
The human GFAP gene maps in chromosome 17q21 (Bongcam-Rudloff et al., 1991) and is 
composed of nine exons and eight introns, plus four alternative exons and two alternative introns, 
for about 10 kb of DNA, and yields a mature mRNA of about 3 kb (Kumanishi et al., 1992). The 
original mRNA transcript can give birth, by alternative splicing, to six different isoforms of the 
protein, the most abundant one being GFAPα (Reeves et al., 1989; Zelenika et al., 1995; Nielsen 
et al., 2002; Hol et al., 2003; Roelofs et al., 2005; Blechingberg et al., 2007).  
Originally thought to be an astrocyte-specific IF, GFAP has now been detected even in non-glial 
and non-CNS cells, like  chondrocytes (Kepes et al., 1984; Hainfellner et al., 2001), ﬁbroblasts 
(Hainfellner et al., 2001), myoepithelial cells (Viale et al., 1991; Hainfellner et al., 2001), 
lymphocytes (Riol et al., 1997) and liver stellate cells (Carotti et al., 2008).  
However, possible structural differences between central  and  peripheral  GFAP  molecules have 
been suggested (Feinstein et al., 1992). 
GFAP gene expression is regulated by the GFAP promoter (Eng et al., 2000), which it is induced 
by multiple factors such as brain injury and disease fluctuates under the circadian light-dark 
cycle (Hajos, 2008).  One well known element of the basal promoter is the so called TATA-box 
which binds the general transcription factor IID (TFIID) (Nakatani et al., 1990). However there 
are multiple sites of the promoter which are likely to regulate GFAP expression [reviewed in 
(Middeldorp and Hol, 2011)], and epigenetic mechanisms like phosphorylation and DNA 
methylation can have significant effects on gene transcription. 
In the mouse CNS, GFAP is the major IF protein in the adult brain and is a characteristic protein 
of mature astrocytes. GFAP expression begins at the end of gestation, while there are not clear 
data about the age of onset of its production in humans, though it is thought to begin at gesta-
tional week (gw) 9–12 (at 6 gw already in some studies) (Antanitus et al., 1976; Stagaard and 
Mollgard, 1989; Honig et al., 1996; Simonati et al., 1997; Messam et al., 2002; deAzevedo et al., 
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2003; Middeldorp et al., 2010). Gene transcription increases between birth and day 15 and then 
decreases until day 55 (Riol et al., 1992). After reaching a plateau lasting into the second year of 
adult life, GFAP mRNA and protein levels increase again in  hippocampus, striatum and cortex,  
usually corresponding to the increase of reactive astrocytes that during senescence is one of the 
most generalized markers for brain aging (Morgan et al., 1997; Morgan et al., 1999). In more 
general terms, the enlargement of astrocytes and the increased expression of GFAP is an indica-
tion of  reactive gliosis, a process which has shown to be highly related to brain damage and ag-
ing and is related to decreased astrocyte proliferation (Eng and Ghirnikar, 1994). 
GFAP is thought to help to have mainly mechanical roles,  modulating astrocyte motility and 
shape and providing structural stability to astrocytic processes. Moreover, some data indicate that 
GFAP might play an important role in the control of neurological disease and response to injury 
by limiting the lesions (Maragakis and Rothstein, 2006). 
Although GFAP function in brain physiology and pathology is still controversial, a large amount 
of evidence has been accumulating in the past years in favor of an active and relevant role for 
this structural intermediate filament protein in brain development (Middeldorp and Hol, 2011). 
 
Vimentin 
 
Vimentins are class-III intermediate filaments found in various non-epithelial cells, especially 
mesenchymal cells. It was found in astrocytes, fibroblasts, endothelial cells, macrophages, 
neutrophils and lymphocytes (Evans, 1998).  
Vimentin biological function is not clear at the present time. We know that in the course of as-
trocyte development, a transition in the expression of IF protein genes is observed. Early during 
development, radial glia and immature astrocytes express mainly vimentin. Towards the end of 
gestation, a switch occurs whereby vimentin is progressively replaced by GFAP in differentiated 
astroglial cells, although certain astrocytes also co-express GFAP and vimentin in the adult ani-
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mal, mainly the Bergmann glia and the astrocytes in the corpus callosum, and the hippocampus, 
although in a variable manner in the latter one (Stichel et al., 1991; Missler et al., 1994; Kalman 
et al., 1998). 
Data obtained from vimentin knockout mice (-/-) demonstrated that those animals developed and 
reproduced without presenting an obvious new phenotype, thus heavily calling into question the 
biological function of vimentin. Several data, however, argue in favor of a relevant function for 
vimentin. In vimentin (-/-) lineages, cells that normally co-express vimentin and GFAP do not 
present GFAP filament. Transfection of cultured vimentin -/- astrocytes with a vimentin cDNA 
restores the vimentin-GFAP filament network, suggesting that in these cells vimentin might be 
required for co-assembly with GFAP filaments (Goldman et al., 1996). 
 
NGF and its receptors  
 
The neurotrophins are a four-member peptide growth factor family that includes nerve growth 
factor (NGF) (Levi-Montalcini, 1952), brain-derived neurotrophic factor (BDNF) (Leibrock et 
al., 1989), neurotrophin 3 (NT-3) (Maisonpierre et al., 1990), and neurotrophin 4/5 (NT-4/5) (Ip 
et al., 1992), which exhibit well-described actions in the nervous system. Classically defined as 
target-derived survival factors for developing neuronal populations, the roles of the 
neurotrophins are now known to include growth cone guidance, synaptic modulation, injury 
protection, and influence on memory and behavior (Levi-Montalcini, 1987; Barde, 1989). 
All neurotrophins are translated from single coding exons as larger precursors (proneurotrophins) 
of ~30–34 kDa that rapidly associate as noncovalent homodimers. Proneurotrophins can be 
cleaved in the ER and Golgi to produce C-terminal mature neurotrophins (~13 kDa) (Shooter, 
2001). 
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At the molecular level, proneurotrophins and mature neurotrophins interact with two distinct 
type of receptors: p75
NTR
, one of the tumor necrosis factor superfamily of receptors (Chao et al., 
1986; Johnson et al., 1986), and tropomyosine related kinase receptors, Trks (Barbacid, 1993) 
(Fig. 3).  
 
Figura 3 Neurotrophin–receptor interactions. This illustrates the major interactions of each of the four 
mammalian neurotrophins. Each proneurotrophin binds p75NTR, but not the Trk receptors. Following 
maturation through proteolysis of the proneurotrophins, each mature neurotrophin is able to bind and 
activate p75NTR, but exhibits more specific interactions with the three Trk receptors. NGF binds specifically 
TrkA; BDNF and NT4 recognize TrkB; NT3 activates TrkC. In some cellular contexts, NT3 is also able to 
activate TrkA and TrkB with less efficiency. For simplicity, only the major tyrosine kinase-containing 
isoforms of the Trk receptors are depicted. Differential splicing generates isoforms of TrkB and TrkC that 
have truncated cytoplasmic domains lacking a tyrosine kinase motif. Splicing also generates an isoform of 
TrkC with a small insert in the kinase domain that affects substrate specificity. Splicing of exons that generate 
the extracellular domain of each Trk receptor results in the expression of receptors with small peptide inserts 
between the second immunoglobin and transmembrane domains that affect ligand-binding specificity. 
Ligand-binding specificity is also affected by the presence of p75NTR [adapted from (Reichardt, 2006)]. 
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Indeed most neurotrophin actions on neuronal differentiation and survival can be ascribed to this 
coreceptor system.  Trk receptor tyrosine kinase is the specific signaling entity for each 
neurotrophin while p75
NTR
 serves to restrict and augment ligand recognition specificity 
(Hempstead et al., 1991).  
Nerve growth factor (NGF) is the member of the neurotrophin family that was first to be 
discovered and purified. It supports neuronal survival during development and influences 
neuronal function throughout adulthood. 
In particular, it influences development of sensory and autonomic neurons in the peripheral 
nervous system (Levi-Montalcini, 1987), and of basal forebrain cholinergic neurons in the CNS 
(Mobley et al., 1986). During adulthood plays an essential role in pain transmission (Pezet and 
McMahon, 2006) and in the maintenance of the cholinergic phenotype of the CNS (Mufson et 
al., 2008).  
It sends its survival signals through activation of TrkA receptor (Kaplan et al., 1991; Klein et al., 
1991) and can induce death by binding to p75(NTR). Neurotrophin engagement of Trk receptors 
leads to activation of Ras, phosphatidylinositol 3-kinase, phospholipase C-γ1 and signaling 
pathways controlled through these proteins, including the mitogen-activated protein kinases (Fig. 
4).  
 
Figura 24 Summary of the NGF signaling pathways. Adapted from Nicol and Vasco, 2007(Nicol and Vasko, 
2007) . 
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NGF, like the other neurotrophins, is translated as a pre-pro-protein (Shooter, 2001). Two 
splicing variants lead to the formation of a long and a short form of precursor protein (Fig. 5A), 
both glycosylated in vivo, yielding different molecular weight forms identified (Reinshagen et 
al., 2000; Lee et al., 2001; Fahnestock et al., 2004; Fasulo et al., 2005; Pagadala et al., 2006; 
Mouri et al., 2007; Nomoto et al., 2007).  
The signal peptide mediating secretion is cleaved upon translocation into the endoplasmic 
reticulum. In the trans-Golgi network, the pro-peptide is further processed by furin at a 
conserved dibasic amino acid site, resulting in the release of the 26 kDa mature neurotrophin 
(Seidah et al., 1996; Mowla et al., 1999; Fahnestock et al., 2004; Mouri et al., 2007; Nomoto et 
al., 2007). 
 
Figure 5 Schematic representation of the major translation products arising from alternative splicing of the NGF 
transcript: the long pre-proNGF form of 34 kDa (a) and the short pre-proNGF form of 27 kDa (b). 
 
Recently it was found that in cultured neurons, proNGF exhibits a higher affinity for p75
NTR
 than 
for TrkA, determined by the coexpression of the coreceptor sortilin (Nykjaer et al., 2004), and 
can induce p75
NTR
-dependent apoptosis (Lee et al., 2001; Harrington et al., 2004; Pedraza et al., 
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2005). ProNGF can also bind to TrkA and induce neuronal survival, although to a lesser extent 
than mature NGF. ProNGF is the predominant form of NGF in normal brain, but its synthesis is 
up-regulated in various pathological conditions, including AD, and can elicit apoptosis of BF 
neurons even when Trk receptors are activated (Volosin et al., 2006) (see “NGF and Alzheimer: 
The emerging complexity of the proNGF/NGF system”). 
Thus, the balance between cell death and cell survival might be determined by the ratio of 
proNGF and mature NGF secreted by cells.  
 
Figure 6 Possible scheme for the signaling of NGF and proNGF, involving Sortilin receptor, besides the “traditional” re-
ceptors p75NTR and TrkA. 
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Astrocytes and NGF 
 
Several cell culture studies showed that NGF can be synthesized and secreted from embryonic or 
neonatal astrocytes (Furukawa et al., 1986; Tarris et al., 1986; Assouline et al., 1987; Furukawa 
et al., 1987; Yamakuni et al., 1987; Rudge et al., 1992; Moretto et al., 1994; Condorelli et al., 
1995).  
Rodent cultured astrocytes express both p75 (Marchetti et al., 1987; Hutton et al., 1992) and 
TrkA NGF receptors (Hutton et al., 1992; Hutton and Perez-Polo, 1995). The expression of both 
receptors can be increased by NGF itself (Kumar et al., 1993; Hutton and Perez-Polo, 1995). 
An autocrine regulation mechanism has been recently found according to which Nerve growth 
factor attenuates proliferation of astrocytes via the p75 neurotrophin receptor (Cragnolini et al., 
2009).  
No regional differences were detected, in terms of amount of NGF in astrocytes. Among cultures 
of glial cells of hippocampal, cortical, striatal, hypothalamic or mesencephalic origin, levels of 
NGF released by the cells were very similar (Houlgatte et al., 1989; Gonzalez et al., 1990). They 
are closely correlated to the growth rate as shown by the fact that exponentially growing cells 
produced relatively more factor than did confluent cell .  
In these cultures, NGF synthesis/secretion can be differentially regulated by several factors, and 
this regulation is different according to the state of the cells. NGF production can be increased by 
glutamate, cathecolamines and dopamine agonists in quiescent astrocytes while the same cate-
cholamines and noradrenaline  decrease NGF content in growing cells (Furukawa et al., 1987; 
Lu et al., 1991; Pechan et al., 1993; Inoue et al., 1997; Culmsee et al., 1999; Ohta et al., 2000; 
Ohta et al., 2003). Cholinergic agonists, such as metacholine and carbamylcholine, nicotine and 
nicotine agonists slightly increased the NGF content in quiescent cells, but showed no effects on 
growing astrocytes (Furukawa et al., 1987; Martinez-Rodriguez et al., 2003)  
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All cathecolamines act on NGF synthesis at transcriptional level, by increasing mRNA content in 
astrocytes (Furukawa et al., 1989). Cyclic AMP (Schwartz and Mishler, 1990). Stimulation of 
adenosine or serotonin receptors induces the release of NGF (Ciccarelli et al., 1999b; Rathbone 
et al., 1999; Krzan et al., 2001; Wittendorp et al., 2004). Changes in aminoacid and ionic concen-
tration, and particularly an increase in Tryptophan or [K+] content stimulate respectively NGF 
synthesis (Dong-Ruyl et al., 1998) and secretion from cultured astrocytes (Abiru et al., 1998).  
Inflammatory cytokines like Interleukin1 α and β (Gadient et al., 1990; Spranger et al., 1990; 
Carman-Krzan et al., 1991; Yoshida and Gage, 1992; Juric and Carman-Krzan, 2001; Miklic et 
al., 2004; Jauneau et al., 2006), Interleukin-6 (Marz et al., 1999; Ales et al., 2008) , Tumor ne-
crosis factor α (Gadient et al., 1990; Yoshida and Gage, 1992; Miklic et al., 2004; Kuno et al., 
2006), transforming growth factor β1 (Lindholm et al., 1990; Yoshida and Gage, 1992; Yu and 
Fahnestock, 2002), Interleukin-4 (Boutros et al., 1997; Brodie et al., 1998), Interferon- (Boutros 
et al., 1997), Interleukin-8 (Kossmann et al., 1997), Interleukin-10 (Brodie, 1996), Interleukin 4 
and 5 (Awatsuji et al., 1993) and inflammatory/oxidative stress related factors such as Platelet 
activating factor (PFA) (Brodie, 1995), thrombin (Neveu et al., 1993) histamine and its related 
receptor H1 (Lipnik-Stangelj and Carman-Krzan, 2004b, a; Miklic et al., 2004; Ales et al., 2008), 
anaphilatoxins (Jauneau et al., 2006), prostaglandins (Toyomoto et al., 2004) and nitric oxide 
(Xiong et al., 1999) were showed to have an enhancing effect on the production of NGF in astro-
cytes, providing a molecular link between inflammation and astrocytic synthesis of NGF 
(Lipnik-Stanglj and Carman-Krzan, 2000; Guo et al., 2001). 
Different growth factors such as acidic and basic fibroblast growth factors (aFGF and bFGF) and 
ciliary neurotrophic factor (CNTF) significantly increase NGF secretion by astrocytes 
(Fukumoto et al., 1991; Ono et al., 1991; Yoshida and Gage, 1991; Semkova and Krieglstein, 
1999; Cassina et al., 2005),while epidermal growth factor fails to increase NGF synthesis in cul-
tured rat astrocytes (Vige et al., 1991). Synthesis of NGF can be also enhanced by glycerophos-
pholipids, sphingolipids, and their related compounds (Galve-Roperh et al., 1997; Furukawa et 
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al., 2007), retinoic acid (Ahlemeyer et al., 2000), 1,25-dihydroxyvitamin D3 (Neveu et al., 
1994a; Neveu et al., 1994b) and glucocorticoids hormones (Lindholm et al., 1992).  
In cultures of immature astrocytes, NGF induces proliferation of GFAP-positive cells 
(Yokoyama et al., 1993), possibly by stimulating mitosis as well as enhancing survival or diffe-
rentiation. Moreover, increases expression of the neural adhesion molecule L1, leading to a glia-
mediated L1-specific increase in neurite outgrowth of dorsal root ganglion neurons on the astro-
cyte substrate (Saad et al., 1991). 
In pathological conditions, increased NGF synthesis/secretion by astrocytes is found in astrocy-
tomas (Saito et al., 2006), gliomas (Fukumoto et al., 1994). 
All the data described so far were obtained from astrocytes cultured in vitro. In vivo, conflicting 
results have been  reported. Bacia et al al. did not found localization of NGF in hippocampal as-
trocytes (Bacia et al., 1992). Astrocytes in brain tissue from human subject do not express, in 
normal conditions, NGF or TrkA (Calatozzolo et al., 2007). In adult rats, NGF receptors are ex-
pressed in small, poorly ramified cells (Soltys et al., 2003) in the hippocampal dendritic fields 
(McCarthy et al., 2002). On the contrary, spinal cord from matured or aged rats express TrkA 
(Oderfeld-Nowak et al., 2003).  
However, increasing evidence is recently accumulating that, although in intact brain the main 
source of NGF are target neuronal cells, in some pathological conditions an increase in extra-
neuronal pool of NGF takes place. Several lines of evidence indicate that in noxious conditions 
astrocytes behave just as the astroglia in vitro and thus are an important site of NGF production 
in damaged brain. The rise of NGF levels in brain in various models of reactive gliosis has indi-
rectly shown that brain astrocytes can synthesize the nerve growth factor. Moreover, in several 
cases NGF immunoreactivity has been directly revealed in activated astrocytes.  
In neurotoxic damage a large increase in total NGF content in the hippocampus was observed 
(Bakhit et al., 1991; Chen et al., 2006; Volosin et al., 2008) but, pyramidal and granular layer 
neurons, which produce NGF under normal conditions, were lost and a large increase in GFAP 
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immunoreactivity was seen instead. In general, NGF synthesis in astrocytes is upregulated in a 
number of stress or damage condition, like toxic or mechanic damage (Junier et al., 1994; 
Strauss et al., 1994; Rudge et al., 1995; Kossmann et al., 1996; Rossner et al., 1997; Goss et al., 
1998; Wu et al., 1998; Koczyk and Oderfeld-Nowak, 2000; Yu and Fahnestock, 2002), oxidative 
stress (Pechan et al., 1992; Naveilhan et al., 1994), apoptosis (Pehar et al., 2004), ischemia (Lee 
et al., 1996; Himeda et al., 2007; Tonchev et al., 2008; Tonchev, 2011), multiple sclerosis and 
experimental autoimmune encephalitis (Micera et al., 1998; Biernacki et al., 2005), amyotrophic 
lateral sclerosis (Barbeito et al., 2004).  
Furthermore, hippocampal astrocytes incubated with Aβ up-regulate NGF expression (Schulte-
Herbruggen et al., 2007) and release it in the culture medium, causing tau hyperphosphorylation 
and death in co-incubated p75 expressing neurons (Saez et al., 2006), thus indicating a possible 
involvement of astrocytes in Alzheimer’s disease.  
Reactive astrocytes can induce also neuronal death, being a possible source of pro-NGF 
(Domeniconi et al., 2007). In stress conditions, like in response to peroxynitrite, an oxidant and 
producer of free radicals, (Vargas et al., 2004) or to kainic acid (Volosin et al., 2006) astrocytes 
up-regulate the levels of pro-NGF production. Cultured motor neurons viability is sensitive to 
conditioned media from cultured astrocytes treated with peroxynitrite, an effect that could be re-
versed using a specific antibody against the pro-domain of pro-NGF.  
On the other side, many astrocytes not only synthesize NGF and pro-NGF, but also the receptors 
TrkA and p75. The production of NGF receptors in several human diseases (Aguado et al., 1998). 
NGF receptors were found to be up-regulated in rats following ischemic damage (Lee et al., 
1998; Oderfeld-Nowak et al., 2003; Soltys et al., 2003), multiple sclerosis lesions (Oderfeld-
Nowak et al., 2001; Valdo et al., 2002; Oderfeld-Nowak et al., 2003), neurotoxic damage 
(Koczyk and Oderfeld-Nowak, 2000).  In p75 expressing cultured astrocytes, NGF fails to in-
duce an autoapoptotic reaction, but it attenuates the cellular proliferation (Cragnolini et al., 
2009). 
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The presence of p75NTR and TrkA receptors in reactive astrocytes from different human neuro-
degenerative diseases and experimentally induced models in rats, and in neoplastic astrocytes 
suggests that NGF may participate in the astroglial response to different types of injury and  
neoplastic proliferation (Hutton et al., 1992; Brown et al., 2008). Since astroglial cells are capa-
ble of producing NGF, it is plausible that this neurotrophin may function as an autocrine or para-
crine factor in TrkA-expressing reactive and neoplastic glial cells. 
 
Astrocytes and neurodegenerative diseases 
 
Astrocytes, in accordance with their homoeostatic function, are deeply involved in neural 
diseases. Acute and chronic brain insults trigger a specific glial reaction, generally known as 
reactive astrogliosis, represented by a complex morpho-functional remodelling of astrocytes 
(Sofroniew, 2005, 2009). Astroglia forms the first line of brain defense by controlling the 
volume and composition of extracellular space. At the very same time astroglial cells can 
contribute to neuronal damage, when, for example, severe insults compromise astrocyte 
metabolism (Giaume et al., 2007). Recently, astrocyte dystrophy has been connected also to 
different kinds of neurodegenerative diseases, including dementia (Maragakis and Rothstein, 
2006). In particular, both astrogliosis and astroglial dystrophy are manifest in different types of 
dementia. Furthermore, both these processes may develop in parallel depending on the disease 
form and/or stage. The frontotemporal dementia, is, for example, associated with a very early 
and profound apoptotic death and dystrophy of astrocytes (Martin et al., 2001). The degree of 
astroglial loss directly correlates with the severity of dementia (Broe et al., 2004). Conversely, 
other studies, using postmortem tissues from frontotemporal dementia cases, found prominent 
astrogliosis in the frontal and temporal cortices at the very early stages of the disease, with 
astrocyte densities increasing by 4–5 times of the control (Kersaitis et al., 2004). 
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Astrogliosis also assumes the leading pathological role in thalamic dementia and HIV-1-
Associated Dementia (Vanzani et al., 2006).  
Alzheimer’s Disease 
 
AD is a chronic neurodegenerative disease clinically characterized by cognitive loss in two or 
more domains, including memory, language, calculations, orientation and judgment. In more 
than 90% of cases, AD develops after the age of 65 years, and doubles its prevalence with every 
successive decade of life (Aranda-Abreu et al., 2011). The disease eventually leads to the death 
of affected individuals an average of nine years after diagnosis. These clinical features are the re-
sult of neuronal death and dysfunction in the cerebral cortex, entorhinal area, hippocampus and 
basal forebrain, eventually resulting in severe dementia. Pathologically, the three hallmark find-
ings of the disorder are cholinergic deficit (Bartus et al., 1982; Whitehouse, 1992), neurofibril-
lary tangles (Grundke-Iqbal et al., 1986) and extracellular senile plaques composed by the β-
amyloid protein (Glenner, 1988; Selkoe et al., 1988).  
Since in CNS BFCNs provide major projections to the cerebral cortex and the hippocampus and 
cortical cholinergic mechanisms, they are directly involved in superior cognitive functions such 
as learning and memory (Hefti et al., 1984; Hefti and Weiner, 1986; Fischer et al., 1987) and for 
these reason the disease was first attributed to a decrease in cholinergic innervation of the brain 
(Bartus et al., 1982). More recently, with the discovery of the negative effects of  β-amyloid on 
learning and memory capabilities, an “amyloid cascade hypothesis” has been formulated 
(Selkoe, 1991; Hardy and Higgins, 1992).  
Several chromosomes have been shown to be implicated in the pathology of AD, including 
chromosomes 1, 14, and 21, associated with the familial early-onset forms of the disease, and 
chromosomes 12 and 19, linked to late-onset forms. However, most cases cannot be explained 
genetically, and thus several hypotheses have been raised over the years in an attempt to explain 
the etiology of this complex disease (Aranda-Abreu et al., 2011). 
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β-amyloid peptide, the principal constituent of neuritic plaques, may have a major role in the 
neuropathology of AD. It is processed from the Amyloid Precursor Protein (APP) the sequential 
actions of the enzymes β-secretase (BACE1) (Vassar et al., 2009) and γ-secretase (De Strooper 
and Woodgett, 2003) in two forms, one 40 amino acids long (Aβ40) and the other 42 amino acids 
long (Aβ42), which differ in their terminal carbon structure (Haass and Selkoe, 2007). Of these 
two forms, Aβ42 is the most prone to aggregation, promoting the formation of oligomers and ag-
gregation into fibrillar amyloid plaques. Soluble Aβ-oligomers possess profound pro-apoptotic 
and synaptotoxic effects, and induce learning deficits and neuronal loss to a substantially higher 
degree than larger assemblies of aggregated fibrillar Aβ. Moreover, high concentrations of Aβ 
oligomers interfere with long-term potentiation (LTP) (Haass and Selkoe, 2007). 
Beside fibrillar Aβ plaques, neurofibrillary tangles (NFTs) represent the second major neuropa-
thological hallmark of AD. They consist of hyperphosphorylated forms of tau protein (p-tau) that 
is assembled into paired helical filaments (PHFs). Tau can be phosphorylated at multiple sites, 
but because of their high diagnostic relevance for AD, p-tau181and p-tau231 isoforms are gener-
ally used in p-tau targeting AD biomarker-studies (Iqbal et al., 2009). 
 
 Astrocytes in Alzheimer Disease 
 
The pathological potential of glial cells in progression of dementia (as well as in other types of 
brain pathology) was originally suggested by Alois Alzheimer himself in 1910 (Alzheimer, 
1910), and is now becoming object of several investigations. Many studies of the AD-related 
pathological potential of astroglia have focused on the investigations of the effects of β-amyloid 
on astrocytes. 
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Human studies 
 
Astrocytes play significant roles during AD. Senile plaques found in the brain of patients with 
AD are surrounded by clusters with active astrocytes, which might be activated by human 
amyloid-β(Aβ), indicating a correlation between this protein and subsequent alterations in 
astrocyte function. Studies have shown that both aggregated Aβ and the intact cores of Aβ 
plaques isolated from human AD brain tissue can stimulate activation of astrocytes (DeWitt et al., 
1998). 
While microglia infiltrate Aβ plaques in AD, astrocytes aggregate around the periphery, walling 
off the plaque. From this location, astrocytes project thick processes that envelop the Aβ plaque 
and thinner branches that infiltrate deep into the plaque interior (Schwab and McGeer, 2008). 
Astrocytes also accumulate neuron derived amyloid material resulting from local 
neurodegeneration. Once substantial accumulation of this debris occurs, the astrocytes 
themselves might undergo cell death, resulting in the formation of GFAP+ amyloid plaques. The 
reason that the astrocytic cytoplasm is accumulated with Aβ42 and neuronal debris lies in the 
fact that Aβ42 binds with exceptionally high affinity to α7 nAChRs on neuronal surfaces. The 
cortical molecular layer is densely packed with fine α7 nAChR-rich dendrite branches emanating 
from underlying neurons. The Aβ42-α7 nAChR complex is present on degenerating dendrites 
and synaptic surfaces, suggesting that astrocyte-mediated clearing of this debris via phagocytosis 
and endocytosis and the targeting of this material to the lysosomal system explains both the 
source of astrocytic Aβ42 as well as its co-localization in astrocytes with other neuron-specific 
proteins, such as α7nAChR and ChAT (Nagele et al., 2003). 
The origin of astrocytic Aβ42 and the mechanism by which it accumulates selectively in 
activated astrocytes and not in their more quiescent counterparts is unknown. Aβ42 found in 
astrocytes could be either internally produced or extracellulary taken up. Since expression of the 
Aβ42 precursor protein (APP) in astrocytes is known to be extremely low, internal production is 
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unlikely to be a major source of accumulated Aβ42. Thus, internalization of extracellular Aβ42 is 
more apparent and could occur via receptor-mediated endocytosis and/or phagocytosis 
(Aldskogius et al., 1999). 
 
Animal models 
 
Alzheimer’s disease, as every other dementia, is a sole prerogative of humans. No animal suffers 
from AD. Hence, efforts were invested in producing relevant animal models of AD. 
The simplest transgenic models are based on the expression of mutated forms of proteins found 
in the familiar form of the disease. Thus, the transgenic mice harbors single-mutated β-amyloid 
related proteins (amyloid precursor protein (APP) or presenilins, (PS). Some of the most 
notorious models were the one developed by Games et al. in 1995, called PDAPP (Games et al., 
1995), the Tg2576 mouse developed by Hsiao et al. in 1996 (Hsiao et al., 1996), and the APP23 
mouse, harboring a double mutated APP protein (Sturchler-Pierrat et al., 1997).  
However, mutations in PS proteins account for the majority of cases of familiar forms of AD. 
Co-expression of PS1dE9 with APP resulted in a viable model that showed accelerated Aβ 
deposition and memory deficits without tangle formation (Savonenko et al., 2005). 
In parallel, pathological tau animals were developed, the first model being created in 1995 (Gotz 
et al., 1995). These transgenic animals showed somatodendritic localization of 
hyperphosphorilated tau, but have not developed neurofibrillary tangle pathology.  
After identification of the pathogenic mutations of tau in FTDP-17, different transgenic models 
with clear neuronal NFT were produced (Gotz et al., 1995; Cassel et al., 2008). 
One of the most advanced AD animal models is represented by the triple-transgenic mice 
developed in 2003 by Salvatore Oddo and Frank LaFerla (Oddo et al., 2003). These animals (the 
3xTg-AD mouse model) harbor the mutant genes for amyloid precursor protein (APPSwe), for 
presenilin 1 PS1M146V and for tauP301L, which is a mutation related to frontotemporal 
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dementia, another neurodegenerative disease. As well as progressively developing plaques and 
tangles, the 3xTg-AD animals also show clear functional and cognitive impairments including 
LTP, spatial memory and long-term memory deficits.  
Olabarria et al, examined the astroglial morphology of 3xTg-AD mice (Olabarria et al., 2010), 
and found a significant reduction in surface area, volume and complexity in mutant mice 
compared to WT. As can be seen in Fig. 7, this difference was progressive with age and became 
particularly significant in 12 month old mice. On a cellular level, this decrease in complexity was 
reflected by reduced number of main processes and their ramification. accumulation.    
 
Figura 7 Bar graphs showing the complexity (a) of glial cytoskeleton by measuring the GFAP area coverage versus vo-
lume ratio of within the molecular layer of the dorsal dentate gyrus of both control and 3xTg-AD mice at different ages. 
(b and c) Bar graphs showing the coverage area (b) and volume (c) of GFAP at 12 months of age in control and 3xTg-AD 
mice; *Po0.05 compared with age matching controls. (d and e) Fluorescence photomicrographs showing GFAP-positive 
cells in control (d) and 3xTg-AD mice (e) at 12 months of age. There is an evident decrease in arborisation, surface area 
and volume in 3xTg-AD mice when compared with matching controls. Adapted from Rodriguez et al., 2009. 
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The same decrease in astrocytes complexity was found in the postmortem brains of dementia 
patients, whose astrocytes showed significant decrease in fractal dimension, thus indicating the 
decreased complexity. Furthermore, the volume of the brain parenchyma occupied by the 
processes of single astrocyte was smaller in demented than in healthy brains (Senitz et al., 1995).  
Confocal images revealed that the specific population of astrocytes surrounding amyloid plaques 
display the typical reactive characteristics (Fig. 8), showing thick processes and enlarged cell 
bodies. Some of these astrocytes closely associated with amyloid plaques showed β-amyloid 
accumulation.  
 
Figura 8 Confocal image showing GFAP-positive (green) reactive astrocytes surrounding b-amyloid plaques 
(red; a). (b) Reactive astrocytes (green) and an astrocyte showing cytoplasmic b-amyloid accumulation (indicated by ar-
rows; colocalisation, yellow) near a neuritic plaque (red). Adapted from Rodriguez et al., 2009. 
 
NGF and Alzheimer’s disease: Rationale for creating an AD mouse model 
based on NGF deprivation 
 
NGF and Alzheimer: the emerging complexity of the proNGF/NGF system.  
 
In the central nervous system (CNS), mature basal forebrain cholinergic neurons depends on the 
availability of NGF for the maintenance of their phenotype and for survival after lesions or CNS 
insults (Hefti et al., 1984; Hefti and Weiner, 1986; Fischer et al., 1987).  
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BFCNs have been identified as the most significant NGF-sensitive target population: they 
express both TrkA and p75NTR NGF (Sobreviela et al., 1994) and are able to retrogradely 
transport NGF from their cortical projections up to their cell  (Seiler and Schwab, 1984). They 
respond to administration of exogenous NGF with an increase of cholinergic phenotypic markers 
(Li et al., 1995; Pongrac and Rylett, 1998), and an extensive evidence now establishes that NGF 
prevents neuronal death or atrophy in BFCNs from the adult brain. 
In AD brains, the level of NGF mRNA are unchanged (Goedert et al., 1986; Jette et al., 1994), 
whereas increased levels of NGF protein can be detected in the cortex and hippocampus, 
associated to a decreased amount of NGF in the basal forebrain (Crutcher et al., 1993; Mufson et 
al., 1995; Scott et al., 1995; Fahnestock et al., 1996). Furthermore, a reduced expression of the 
TrkA receptor has been demonstrated in BFCNs and neocortex from AD brains (Mufson et al., 
1996; Boissiere et al., 1997), and loss of TrkA expressing BFCNs has been described in mild 
cognitive impairment (MCI) and in early AD neuropathological stages (Counts et al., 2004; 
Ginsberg et al., 2006).  
Remarkably, the AD-linked decline in TrkA cortical contents does not occur for the p75
NTR
 
receptor (Ginsberg et al., 2006), determining disequilibrium in the TrkA/p75
NTR
 ratio that might 
have functional consequences (Cattaneo et al., 2008). Therefore, the putative “off Trk” cycle of 
deficient NGF signaling may contribute to the selective degeneration of cholinergic neurons 
observed in AD. 
There are interesting pieces of evidence possibly linking NGF to cholinergic dysfunction and to 
AD. 
NGF is axonally retrotransoported to the somata of the BFCNs, and cytoskeletal transport 
dysfunctions are a common hallmark of AD (Mufson et al., 1995), due to hyperphosphorylation 
of tau and the ensuing microtubule destabilization (Cattaneo et al., 2008). Furthermore, amyloid-
β protein precursor has been shown to have a role in axonal transport (Gunawardena and 
Goldstein, 2001). Thus, a deregulation of intracellular transport mechanisms, by different causes 
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linked to AβPP, tau, and NGF signaling and/or processing abnormalities, might be one crucial 
aspect for initiating a negative neurodegeneration loop in AD, leading to a further reduced 
neurotrophic support to BFCNs (Mufson et al., 1995).  
Beside cholinergic dysfunction and neuronal transport defects, other mechanisms could provide 
a link between an imbalance of NGF signaling and AD. 
ProNGF is the predominant form of NGF in the brain, and its content is increased in AD and 
MCI (Fahnestock et al., 2001; Peng et al., 2004). It can trigger cell death, as shown in cellular 
models using the purified protein (Lee et al., 2001) or AD brain extracts (Pedraza et al., 2005; 
Podlesniy et al., 2006). In addition, evidence was provided linking NGF deprivation to the 
activation of Aβ aberrant processing of APP and tau in vitro (Tan et al., 1999; Matrone et al., 
2008a; Matrone et al., 2008b) and in vivo, from the studies in the anti-NGF AD11 mouse model 
(see below). 
 
 
The AD11 mouse model 
 
The AD11 model was developed in the group of Antonino Cattaneo at the International School 
for 
Advanced Studies, Trieste, Italy (Ruberti et al., 2000). This model expresses a recombinant 
monoclonal antibody called αD11 which neutralizes mature NGF (Cattaneo et al., 1988), 
producing a sequestration of the protein that prevents it from exerting its biological functions. 
This unique mouse model permits study of NGF deficiency and its connection to 
neurodegenerative disorders. The phenotype of the mouse model resembles that of human 
Alzheimer’s disease. 
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The αD11 antibody 
 
αD11 is a monoclonal antibody mAb obtained after long term immunization of rats with mouse 
NGF  (Cattaneo et al., 1988) and it neutralizes the biological action of NGF, in vitro (Molnar et 
al., 1998) and in vivo (Berardi et al., 1994; Molnar et al., 1998). 
The epitope of mAb αD11 on NGF includes the loop region from residues 41–49, which 
participates in the interaction surface between NGF and its high-affinity receptor TrkA and 
distinguishes NGF from other members of the neurotrophin family. A comprehensive functional 
and structural study of MAb αD11 showed that it not only prevents NGF from binding to TrkA, 
but also to p75
NTR
 receptors (Covaceuszach et al., 2008). 
MAb αD11 is characterized by specificity for NGF neutralization. Indeed, the crossreactivity of 
the antibody with other neurotrophins has been analyzed with a bioassay based on embryonic 
chick dorsal root ganglions. MAb αD11 blocks the activity of NGF, but it does not affect BDNF, 
NT3 and NT4/5 functions (Molnar et al., 1998; Capsoni et al., 2000). The implantation of 
hybridoma cells secretin MAb αD11 in the third ventricle transiently decreases the number of 
cholinergic neurons in the basal forebrain, thus demonstrating MAb AD11 activity in vivo 
(Molnar et al., 1998).  
AD11 mice express a recombinant version of MAb αD11. It was obtained by reassembling 
variable regions of the light and heavy chains of mAb aD11 with the human K and g1 constant 
regions, respectively, to facilitate the detection of transgenic antibodies against the background 
of mouse Igs. The chains of the antibody are each placed under the transcriptional control of the 
early region promoter of the human CMV in separate plasmids (Ruberti et al., 1993). 
Time dependent expression of anti-NGF antibody in AD11 
 
As expected for the ubiquitous CMV promoter (Baskar et al., 1996a; Baskar et al., 1996b; 
Ruberti et al., 2000), the VH and VK mRNAs are expressed in different adult organs, including 
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brain, heart, kidney, testis, liver. For both chains the mRNA levels in adult tissues were higher 
than those in neonatal tissues (Ruberti et al., 2000). 
Both antibody chains can be detected in non-neuronal tissues and in many areas of the brain, 
such as cortex, hippocampus, thalamus, olfactory bulb, spinal cord, retina, and cerebellum. The 
association of the heavy and light chains requires that the two chains be coexpressed within the 
same cell. Double-labeling immunohistochemistry demonstrated the coexpression of the two 
chains in a high percentage of neuronal and non-neuronal cells. The number of cells 
coexpressing both antibody chains is much greater in the adult than in the neonatal tissues 
(Ruberti et al., 2000). 
Interesting, while mice in which NGF has been knocked out by targeted mutation die soon after 
birth, the AD11 mice develop normally as anti-NGF mAb levels are low at birth and rise in 
adulthood. Anti-NGF antibody levels are undetectable between E15 and P45, but rise at high 
levels in adult mice (P90) (Capsoni et al., 2000; Ruberti et al., 2000). Free NGF in the brain is 
more than 50% lower in AD11 mice than in control mice (Ruberti et al., 2000). 
 
Neurodegenerative phenotype  in the AD11 model 
 
AD11 mice show a progressive and complex phenotype summarized in Table 2.  
Cholinergic deficit   
 
The primary target of NGF in the CNS are BCNFs. These neurons express both TrkA and 
p75
NTR
 receptors (Sobreviela et al., 1994). the analysis in Ad11 mice was performed using the 
evaluation of the number of neurons expressing the enzyme choline acetyltransferase (CHAT). 
As expected from the time course of the transgenic antibody expression, the number of 
cholinergic neurons is unchanged between 0 and P45, while an initial 10-20% decrease can be 
found at 2 months of age (Ruberti et al., 2000; Capsoni et al., 2002c). The cholinergic deficit 
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increases with age, reaching a 40-50% of decrease in choline acetyltransferase - positive neurons 
at 6 months of age, and being stable thereafter (Capsoni et al., 2002b). 
 
Hyperphopshorylated tau  
 
The temporal progression of tau hyperphosphorylation in AD11 mice has been studied using 
antibodies directed against differente epitopes of phosphorylated tau. 
The antibody that was most useful in characterizing the progression of fibrillar 
neurodegeneration was the antibody directed against Ser202/205, clone At8. 
This antibody showed that at 2 months of age, similarly to what found in AD human brains, 
intracellular phosphorylated tau is localize mainly in the enthorinal cortex (Capsoni et al., 2002a). 
With aging, phospho-tau positive neurons are found in the other cortical areas and in the 
hippocampus (Capsoni et al., 2002c, a). In AD brains , phosphorylated tau accumulates in 
soluble and insoluble forms. By western blot analysis and the use of MAb AT8 and PHF1 
antibody both states of phosphotau were found in brain extracts of aged AD11 mice (Capsoni et 
al., 2000). 
The use of MAb AT8 combined with immunoelectron microscopy on insoluble fractions of brain 
extracts showed that phosphotau accumulates in PHF like structures (Capsoni et al., 2002a).  
 
β amyloid  
 
Amyloidogenic forms of APP, containing Aβ-region epitopes, are produced in the brain of aged 
AD11 mice. Large numbers of amyloid plaques are detectable in the cortex, thalamus, 
hippocampus and other regions. Diffuse nonneuritic plaques (Fig. 9C), compact neuritic plaques 
(Fig 9E) and dense cored nonneuritic plaques are all observed in the brains of AD11 mice, but 
absent from the neostriatum, cerebellum and locus coeruleus (Capsoni et al., 2002c). 
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Extracellular deposits of amyloid beta, but not plaques, are observed as early as six months of 
age (Capsoni et al., 2002a). 
Cerebrovascular Aβ deposition (Fig. 9G) is found consistently throughout cerebral cortex, 
hippocampus, and thalamus of aged AD11 mice with antibodies against Aβ1–40, Aβ1–42 and Aβ17–
24 and is completely absent in nontransgenic mice. Leptomeningeal vessels are also heavily 
affected. Activated microglia is present surrounding plaques and in the parenchyma  (Capsoni et 
al., 2002c). ELISA performed on formic acid brain extracts showed a ratio between Aβ1–40 and 
Aβ1–42 equal to 0.55 (Capsoni et al., 2002c). AD11 Mice display an increased expression of 
presenilin 1 and β-secretase (BACE) (Capsoni et al., 2004). It is important to underline that 
unlike FAD mice, and similarly to sporadic AD, in AD11 mice Aβ pathology derives from the 
endogenous APP in the absence of mutations in APP or AP processing genes. 
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Figure 9 Distribution of β-amyloid plaques in AD11 mice. Immunohistochemistry with antibodies against 
Aβ17–24 on brain sections of aged AD11 mice (A) and nontransgenic control (B) reveals the presence of β-
amyloid plaques in the hippocampus. (C) A central core surrounded and overlayed by Aβ-positive cells 
(arrows) and dystrophic neurites (arrowheads) forms the most abundant form of plaques. (D) Antibodies 
against Aβ17–40 label Aβ plaques in human AD brain. Nonneuritic plaques are detected by antibodies 
against Aβ1–42 and NH2-terminus of Aβ in sections from AD11 mice (E) and human AD brains (F). Cerebral 
amyloid angiopathy is detected in AD11 mice (G) and not in nontrasgenic control mice (H). Arrows point to 
cerebral vessels. Bars in A and B, 360 μm; in C–H, 25µm. Adapted from Capsoni et al., 2002. 
 
 
Imbalance of inflammatory markers 
 
It has been recently proposed that neuroinflammation might be an early event in the pathogenesis 
of AD (Eikelenboom et al., 2010).  
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mRNAs involved in inflammation and immune response are upregulated in young AD11 mices’ 
brain. Differential expression of mRNA for various proteins of the complement system is 
particularly noteworthy compared to WT. Complement C3 mRNA is highly up-regulated at P30 
in cortex (5.10 ratio) and hippocampus (5.16 ratio) and at P90 in all brain areas (9.67 and 11.62 
ratio in cortex and basal forebrain, respectively), C1qa mRNA is up-regulated in cortex and 
hippocampus at P90 and the C1qb is up-regulated in the basal forebrain and the hippocampus at 
P90, while C1qc expression is unchanged in the different brain areas and C2 mRNA is down-
regulated in the BF and cortex at P30 and in the hippocampus at P90 (D'Onofrio et al., 2011). 
The expression of mRNAs coding for Class I Major Histocompatibility Complex (MHC) is also 
altered, with a significant decrease in some areas at P30 and increased at P90 (H2-T23). 
The remarkable, early activation of the complement cascade in the AD11model is noteworthy, 
not only for the role played by complementin in immune response, but also because of the 
recently demonstrated role of the complement system in mediating CNS synapse elimination, 
during normal brain developing (Stevens et al., 2007). The relevant over-expression of some 
complement cascade factors in the AD11 mouse model could mediate the synaptic loss and 
remodeling occurring early in this mouse model. 
These data show an involvement of central components of the innate and the adaptive immune 
response in the early neurodegeneration phases in AD11 mice. 
 
Synaptic deficit  
 
Synaptic failure and subtle alterations of hippocampal synaptic efficacy have been suggested to 
anticipate frank neuronal degeneration (Selkoe, 2002). 
In the cortex, Ad11 show a progressive impairment of long term potentiation (LTP). At 2 months 
of age, LTP can be induced but not maintained (Origlia et al., 2006). This failure can be reverted 
by acute administration of acetylcholine or of the cholinesterase inhibitor galantamine (Origlia et 
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al., 2006). However, the cholinergic treatment did not rescue the impairment of LTP in 9-10 
months old AD11 mice characterized by a severe cortical neurodegeneration, i.e. when LTP is 
not even induced, thus indicating that the impairment is progressive.  
.In the hippocampus of Ad11 mice, synaptic plasticity deficits are subtler. In AD11 nicotine fails 
to modify synaptic strength and to increase the frequency of spontaneous miniature 
glutamatergic currents in hyppocampal CA1 (Rosato-Siri et al., 2006; Sola et al., 2006). This 
occurs via loss of cholinergic function at CA3-CA1 synapses that might be compensated by a 
rearrangement of the γ-aminobutiric acid (GABA)ergic circuit (Sola et al., 2006). Indeed, in 
adult AD11 mice, GABAergic signaling shifts from a hyperpolarizing to an immature 
depolarizing state (Lagostena et al., 2010), which may contribute to or protect from 
neurodegeneration. In general, the excitatory imbalance in AD11 mice is a major event in early 
neurodegeneration and it could contribute to alter hippocampal circuits. 
A recent study has also enlighten that, while CA1 plasticity remains relatively spared, as in 
FAD-based transgenic mice (Palop et al., 2007), also in AD11 short and long term plasticity in 
the dentate gyrus (Houeland et al., 2010).Thus, AD11 mice share with FAD-related mouse 
models several aspects of hippocampal synaptic plasticity and synaptic network deficits.   
 
Memory impairment  
 
Ad11 mice show progressive memory deficits that well correlate with the expression of the 
antibody and the onset of the neurodegenerative phenotypes. 
The first mild deficit appear at 1 month of age, and is revealed by the object recognition test, 
which takes advantage of the natural curiosity of rodents for new objects and consequently of 
their capacity to discriminate old from new objects (Ennaceur and Delacour, 1988). In this test, 
AD11 mice don’t discriminate between new and old objects, and thus they do not remember the 
old object. 
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The early appearance of the working memory deficit in 1 month old AD11 mice might correlate 
with the upregulation of gene and protein related to neurodegeneration. In particular, it might 
correlate with the role played by complement related protein in regulating synaptic functions.  
The deficits in working memory progress with age and becomes severe at 8 months of age, when 
AD11 mice fail to remember objects explored one hour before the last test (De Rosa et al., 2005). 
Spatial memory deficits, involving the hippocampal complex, were analyzed using the Morris 
Water Maze Test. The analysis revealed that AD11 show learning deficits not before 7 months, 
i.e. not before the appearance of Aβ deposits (Capsoni et al., 2002a). Spatial memory deficits 
appear at 10 months of age (De Rosa et al., 2005). The late onset of special memory deficits was 
confirmed using the object localization test (De Rosa et al., 2005). 
 
In summary, the AD11 mice display a comprehensive neurodegeneration that is reminiscent of 
the sporadic forms of AD. 
 
Table 2. Summary of phenotypic characterization in AD11 mice 
 
Phenotypic Markers Brain Areas Age (months) 
  1 2 4 6 8 9 10 12 15 
Detectable anti-NGF antibody in serum and 
brain  
- + + + + + + + + 
Shrinkage of SCG  ND + ND 
N
D 
N
D 
ND ND ND ND 
Shrinkage of DRG   ND + ND 
N
D 
N
D 
ND ND ND ND 
Decreased TrkA expression in trigeminal 
ganglia  
ND + ND 
N
D 
N
D 
ND ND ND ND 
Decreased expression of TrkB or TrkC in 
vestibular and nodose ganglia  
ND - ND 
N
D 
N
D 
ND ND ND ND 
Decreased sympathetic innervation in 
spleen  
ND + ND 
N
D 
N
D 
ND ND ND ND 
Apoptosis in the spleen  ND + ND 
N
D 
N
D 
ND ND ND ND 
Decrease in number of IgG+ lymphocytes  ND + ND 
N
D 
N
D 
ND ND ND ND 
Inflammatory response  ++ ++ ND 
N
D 
N
D 
ND ND ND ND 
ChAT reduction  Basal forebrain - + + ++ ++ ++ ++ ++ ++ 
TrkA reduction Basal forebrain - + + ++ ++ ++ ++ ++ ++ 
P75
NTR
 Basal forebrain - - + ++ ++ ++ ++ ++ ++ 
 
 
 
 
39 
 
Table 2 (continued). Summary of phenotypic characterization in AD11 mice 
 
Phenotypic Markers Brain Areas Age (months) 
  1 2 4 6 8 9 10 12 15 
Hyperphosphorylated tau* 
Entorhinal 
cortex 
- + + ++ ++ ++ ++ 
++
+ 
++
+ 
 Occipital cortex - - + + + + ++ ++ 
++
+ 
Hyperphosphorylated tau* 
Entorhinal 
cortex 
- + + ++ ++ ++ ++ 
++
+ 
++
+ 
 Occipital cortex - - + + + + ++ ++ 
++
+ 
 Parietal cortex - - + + + ++ ++ 
++
+ 
++
+ 
 Hippocampus - - + + + ++ ++ ++ 
++
+ 
Dystrophic neurites (tau-positive) Cerebral cortex - - - - + + ++ ++ 
++
+ 
 Hippocampus - - - - - + + ++ ++ 
ALZ50-positive neurons Cerebral cortex - - - - - - + ++ ++ 
Neurofibrillary tangles (NFT200 antibody) Cerebral cortex - - - - - - - + 
++
+ 
PHF-1-positive neurons Cerebral cortex - - - - - - - - ++ 
Insoluble tau (western blot) Cerebral cortex - - - - - - - - ++ 
 Hippocampus - - - - - - - - ++ 
PHFs Cerebral cortex - - ND 
N
D 
N
D 
ND ND ND ND 
MAP-2 altered distribution Cerebral cortex - + + ++ ++ ++ ++ 
++
+ 
++
+ 
 Hippocampus - - + ++ ++ ++ ++ 
++
+ 
++ 
Accumulation of Aβ Hippocampus - - - + + ++ ++ 
++
+ 
++
+ 
β-amyloid plaques Hippocampus - - - - - - - ++ 
++
+ 
Gallyas staining Hippocampus ND - - 
N
D 
N
D 
ND ND ND + 
Bielschowsky staining Hippocampus ND - - 
N
D 
N
D 
ND ND ND + 
Campbell-Switzer staining Hippocampus ND - + 
N
D 
N
D 
ND ND ND + 
Neuronal loss Cerebral cortex - - - - + + + ++ ++ 
DNA fragmentation Cerebral cortex - - - - - - - - + 
Cortical LTP deficit Cerebral cortex  - + ND ++ 
N
D 
++
+ 
ND ND ND 
Nicotine enhancement failure Hippocampus 
ND ND ND 
+ 
N
D 
ND ND ND ND 
Abnormal GABA excitatory action Hippocampus 
ND ND ND 
+ 
N
D 
ND ND ND ND 
Object recognition test deficit  +/- +/- + + ++ ++ 
++
+ 
++
+ 
++
+ 
Object location deficit   
ND ND ND 
- 
N
D 
ND ND ND ND 
Object context deficit  
ND ND ND 
+ 
N
D 
ND ND ND ND 
Radial Maze (retention)  ND - + - ++ ND ND ND ND 
Morris Water Maze deficit (acquisition)  ND - - - + + ++ ++ ++ 
Morris Water Maze deficit (retention)  ND - - - - - ++ ++ ++ 
*revealed using mAb AT8 
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Aim of the thesis 
 
Our Study was prompted by two observations; 
1) The first observation was obtained by Olabarria (Olabarria et al., 2010) where he 
showed that, while the number of astrocytes in 3xTg mice, a mouse model of FAD, 
remains constant, their volume, surface area, and overall complexity appear to be 
decreased. The authors found a positive correlation between astrocytic atrophy and β-
amyloid deposition. 
2) The second set of data was obtained in our laboratory from two independent studies 
showing that (a) the morphology of astrocytes derived from stem cells isolated from 
the subventricular zone of 6 month-old AD11 mice appears much less complex than 
in WT mice (Fig. 10); (b) in vivo, GFAP-immunoreactive astrocytes from AD11 mice 
of the same age as the previous experiment are less ramified than in WT mice 
(Capsoni et al., 2010b) (Fig. 11). 
 
 
Fig. 10 Astrocytes (in green) derived from stem cells from AD11 mice show a minor degree of morphological complexity 
than AD11 mice. In blue, DAPI counterstaining. From Paolo Capelli Thesis.  
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Fig. 11 GFAP-positive astrocytes (in red) in are more ramified in WT mice than in 6 month-old AD11 mice (from 
Capsoni et al, 2010) 
 
The age of AD11 mice in which these observations were obtained is an interesting one, because 
it coincide with the first appearance of Aβ deposits in the hippocampus (Capsoni et al., 2002a). 
Thus, inspired by Olebarria’s study, we first verified whether astrocyte atrophy and Aβ deposits 
in AD11 mice do correlate. Then, we formulated the hypothesis whereby astrocytic atrophy in 
AD11 mice is due to deprivation of mature NGF. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   A                                 B 
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Materials and methods 
 
    AD11 Mice production 
 
The plasmids pcDNAI-neo/VKαD11HuCK and pcDNAI-neo/VHαD11HuCγ, carrying the light 
and heavy chain genes, respectively, of the chimeric antibody αD11 under the transcriptional 
control of the human cytomegalovirus (CMV) early region promoter [−601 to −16] (Boshart et 
al., 1985), were digested with KpnI–ApaLI and KpnI–XbaI, respectively, to isolate the 
transcriptional units (Fig. 12). The fragments were microinjected in the pronucleus of single-cell 
fertilized C57BL/6 × SJLF2 hybrid mouse eggs, and the injected eggs were reintroduced into 
foster pseudopregnant females of an outbred strain different from that of the microinjected eggs 
(Ruberti et al., 2000).  
 
Figura 12: DNA constructs for the production of the transgenic mice: light chain (top panel ) and heavy chain (bottom 
panel) transgenes. CK and CH1–CH3, Human constant region domains of light (K) and heavy (g1) chains; VK and VH, 
light and heavy chain variable regions of the αD11 monoclonal antibody; CMV, cytomegalovirus promoter. Adapted from 
Ruberti et al., 2000. 
 
Two founder mice with the light chain transgene, two with the heavy chain transgene, and three 
double transgenic mice were generated, but despite an intensive breeding program, no offspring 
were generated. Mice homozygous for the αD11 heavy chain transgene (VH-αD11 mice, lines C 
and D) and mice homozygous for the αD11 light chain transgene (VK-αD11 mice, lines A and B) 
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were generated from the corresponding founders, by at least two crossings. Homozygosity was  
verified by genomic PCR analysis on offspring obtained by crossing putative homozygous to 
negative mice (at least two independent litters for each homozygous line). To obtain mice 
expressing both chains, and thus reconstituting NGF binding activity, single transgenic mice 
were intercrossed in different combinations. 
 
Figura 13: Crossing mice expressing the light chain (cytomegalovirus [CMV]-VKαD11) with mice expressing the heavy 
chain (CMV-VHαD11) yields double transgenic offspring, which express a functional αD11 antibody (anti-NGF mice). 
Adapted from Ruberti et al., 2000. 
 
 
DNA extraction 
 
Genomic DNA was extracted from tails fragments of about 1 cm of length, from 6 months 
old transgenic AD11 mice (9 mice) and age matched WT control mice (7 mice). The 
extraction consisted in a series of successive passages, the first one providing for cellular 
lysis  and digestion of the proteic matrix, obtained by addition, respectively, of 500µl  TB 
Buffer (2.5 ml Tris – HCL 50 mM pH 8, 10 ml EDTA – Ethylenediaminetetraacetic acid – 
100mM  pH 8, 1 ml NaCl 100 mM, 5 ml SDS al 1%,31.5 ml bidistilled sterile H2O) and 0.6 
mg/ml Proteinase K.  
The sample is incubated in termomixer, 55°C, 1200 rpm, for 2 hours to overnight (O.N). 500 
µl of the organic phases from a phenol-chloroform solution (25 ml phenol, 24 ml chloroform, 
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1 ml isoamylic alcohol, few scales 8–hydroxyquinolone, 2 ml Tris–HCl 0.1 M pH 7.4), 
which determines the separation of lipids and DNA proteins by trapping them in the organic 
phase of the solution. 200 µl of the aqueous phase are then drown and put into an eppendorf 
vial containing 400 µl of cold (-20°C) absolute ethanol (100%), which determines the 
precipitation of the DNA (pellet formation). In each of the passages it is necessary to briefly 
vortex the solution in order to facilitate the interaction among the reagents, and consequently 
the desired reaction. Each vortexing is followed by 5 min of centrifugation, 4°C, 12000 rpm. 
The next passage consists in drawing out the alcohol and adding about 200 µl cold (-20C°) 
ethanol 70%  to wash the pellet, and subsequently 5 min. centrifugation, 4°C, 12000 rpm. 
The alcohol is then drown out and the pellet is left to dry under the hood, then re-suspended 
in 250 ml bidistilled sterile H2O and kept at 37°C for 5 min to allow DNA melting. 
 
PCR (Polymerase chain reaction)   
 
The genomic regions containing the coding sites for the heavy (Vh) and light (Vk) chains 
which constitute the αD11 antibody have been amplified by PCR (Polymerase Chain 
Reaction) using specific primers. 
The PCR is a method through which it is possible to amplify a specific DNA fragment 
thanks to the use thermostable DNA-polymerase (RedTaq-polymerase, Sigma-Aldrich, St. 
Louis, Mo), able to work even at very high temperatures, and of specific oligonucleotides 
complementary to the flanking sequence of the site of interest.   
PCR consists in three phases: 
 DNA denaturation (from 92 to 95°C), phase of separation of the two DNA filaments; 
 Annealing (from 50 to 70°C), phase of binding of the specific primers to the com-
plementary fragments of DNA from the site of interest; 
 Extension (from 69 to 72°C), extension of the specific fragment.  
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PCR cycles vary in number from 20 to 35 and the reaction progresses inside a thermocycler 
able to vary the temperature. 
To amplify the regions of interest the sequent conditions were used: the PCR was realized in 
a total volume of 20.5 ul per sample, and was prepared in a sterile eppendorf vial containing: 
14.4 µl bidistilled sterile water, 2 ul 10x Buffer, 0.4 µl dNTPs (for a concentration of 2.5 
mM), 0.7 µl Taq polymerase, 1 µl 5’ and 3’ primers for PCR and 1 µl sample DNA.  
The total number of amplification cycles for both the αD11 VH and the αD11 VK transgene 
has been 30. Timing and temperature conditions for each cycle were: 5’ 95°C; followed by 
30 cycles constituted by 1’ at 95°C, 1’ at 65°C, 1’ at 72°C; and a final phase at 4°C, which 
can last up to 24h.  
For the amplification of the αD11 Vh transgene, the following 5’ and 3’primers were used:  
 αD11 Vh back, ; 5’ gacattcagctgacccagtctcca 3’; 
 αD11 Vh for; 5’ cgtccgaggataatggaaatagtgctg 3’; 
For the amplification of the αD11 Vk transgene, the following 5’ and 3’primers were used:   
 Vk1 back, 5’ caggtgcagctgcaggaatcaggacct 3’;  
 CD3 Vk αD11, 5’ tagggagacggtgaccgaagttccttgacc 3’;  
The final products were analyzed by electrophoresis on agarose 1% and visualized on 
transilluminator. 
 
Tissue collection and processing 
  
One, two and six month-old AD11 and WT mice were anaesthetized with an excess of  2,2,2-
tribromethanol (400 mg/kg) and intracardially perfused with a 4% solution of paraformaldehyde 
in PBS. Brains were collected and post-fixed in the same solution for 4 hours. Brains were 
transferred in 30% sucrose/PBS solution and then sectioned at a sliding freezing microtom 
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(Leica, Wetzlar, Germany). Forty micrometers sections were collected in 0.05% sodium 
azide/PBS in 1.5 ml tubes and stored at 4°C until usage. 
 
Immunohistochemistry 
 
For this labeling, we used the antibodies to GFAP, or combined GFAP immunostaining with 
antibodies against β-amyloid. Morphology of GFAP-positive astroglial profiles was 
reconstructed from series of optical confocal planes taken from 40 µm thick fixed brain slices. 
The cortical sections were treated as follows: 
 
1) Washed 3 times for 10 min in TBST (TBS+TritonX 0.3%) . 
2) 30 min. in TBS+H2O2 3.5% 
3) Washed again 2 times for 10 min in TBST 
4) 30 min. pre-incubation in FBS (TBST+FBS 10%), RT. 
5) Incubation overnight with primary mouse anti-GFAP antibody (1:1000; clone G-A-5 
directed against  the C-terminal Cys II fragment and N-terminal part of the tail sequence 
of GFAP;   Sigma-Aldrich, St. Louis, Mo) in FBS 10%, -4 C°, or for 72h with anti-
GFAP+ goat anti-Aβ antibody (1: 100; Santa Cruz Biotechnology Inc., Santa Cruz, CA). 
6) Washed 3 times for 10 min in TBS 
7) 3 h incubation with secondary sheep anti-mouse antibody Cy3 (1:100; Sigma-Aldrich) 
and   AlexaFluor488 donkey anti-goat (1:100, Invitrogen)  in FBS (TBS+FBS 10%), RT. 
8) Washed 2 times in TBS. 
9) Mounted on gelatin-coated slides with fluoromount adhesive (Sigma-Aldrich, St. Louis, 
Mo). 
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Fluorescence microscopy 
 
Cell counts were performed manually on images take with a Axiophot fluorescence microscope 
(Zeiss, Milano, Italy), with the aid of the cell counter instrument ImageJ software (NIH version 
1.44P). . 
 
Confocal microscopy and image analysis 
 
To study the localization of Aβ and dendrites in hippocampal section from AD11 and WT mice 
we used a confocal laser scanning microscope (TCS SP2; Leica Microsystem, Wetzlar, Germa-
ny) 
Cells used for the analysis were protoplasmic astrocytes from the molecular and radiate layer of 
the hippocampus. They were chosen randomly between the ones entirely encompassed in the 
depth of the slice.  
Image elaboration and analysis was conducted using Bitplane’s software Imaris (Zurich, 
Switzerland). The “filament” function,  was used to reconstruct the exact shape and length of the 
cell processes, then data were extracted about cellular volume, total length of the processes, 
mean diameter, total surface area, number of branching points, number of terminal points. For 
astrocytes from 6-month old mice, total volume of amyloid deposits associated with single 
astrocytes was also measured (we considered the deposits in the area occupied by the branches of 
the cells “associated”). 
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Figura 14: 3D image of an astrocyte from a WT mouse (upper panel), reconstruction of the 3D structure of the processes 
on Imaris (lower panel). Red: anti-GFAP, green: anti-Aβ protein 
 
ELISA to dected free NGF 
 
Elisa test was used to assess the plasmatic level of  free NGF (not bound to the recombinant 
α in blood serum. 
αD11 antibody stock (1 mg/ml) was diluted to 500 ng/ml in 0.5 M Sodium carbonate solution 
(pH 9.5) and used in an amount of 50 μl/well to coat a 96 well plate (Nunc, Roskilde, DK). 
The incubation was performed in a humid chamber overnight at 4 C. The plate was washed 
3 times with PBST (0.05% Tween 20 in 0.1 M phosphate buffered saline (PBS), pH 7.4) and 
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3 times with PBS and incubated at 37 C for 2 hours with 2% Bovine serum albumin 
(BSA)/PBS (100 µl/well).  
A standard curve was prepared using the mouse NGF (Paoletti et al., 2009) as standard. 
The preincubating solution was discarded from the plate. Standards and samples (1:2 in 2% 
milk/PBS) were distributed, in duplicate, in the plate (50 µl /well) and incubated for 2 hours 
at room temperature.  
The plate was washed 3 times with PBST and 3 times with PBS.  
A solution (the amount is determined by the number of samples) with rabbit polyclonal anti-
NGF antibody (1:1000; Sigma-Aldrich) in 2%BSA/PBS was distributed in wells with 
standards and samples. The incubation lasted for 2 hours at room temperature. This solution 
was not distributed in samples that were than used to calculate the values due to nonspecific 
reaction.  
The plate was washed 3 times with PBST and 3 times with PBS. 
A solution (the amount is determined by the number of samples) with biotinylated anti-rabbit 
antibody (1:5000; Sigma-Aldrich) in 2%BSA/PBS was distributed in wells with standards 
and samples. The incubation lasted for 1 hour at room temperature. 
The peroxidase conjugate Avidin/Biotin kit (Vector Labtek) was diluted 1:1000 in PBS and 
incubated for 40 min. at room temperature. The plate was washed 6 times with PBS. The 
reaction was developed using the TMB reagent (Sigma, St Louis, MO, cat. # T-8665) and 
blocked with 1 N HCl and read with a microplate reader (Bio-Rad Laboratories, Hempstead, 
UK) at 450 nm.  
 
Statistical Analysis 
 
Statistical analysis was conducted using the Microsoft Excel Plug-in “Analyze-it”. Outliers were 
identified and discarded using the Shapiro-Wilk test. Normality was assessed for single 
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parameters in the samples. Parameters positive for normal distribution were compared using t-
student test, parameters negative for normality test were compared using Freidman and 
Wilcoxon tests. Correlation between cellular features and levels of amyloid was assessed 
calculating Pearson’s and Spearman correlation coefficients.  
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Results 
 
According to some preliminary observation, astrocytes from AD11 mice brain have a peculiar, 
elongated morphology. This appears particularly evident in in vitro cultures obtained from stem 
cells from the subventricular zone of mutant mice. 
In this work, an analisys of astroglial morphology and Aβ deposits distribution in AD11 and 
control mice grouped by age (1, 2 and 6 month) was performed, in order to confirm the presence 
of glial atrophy in mutants and to check for correlations between astrocytes features and different 
levels of β-amyloid protein. 
The age of AD11 mice at which the preliminary observations were obtained is an interesting one, 
because it coincide with the first appearance of Aβ deposits in the hippocampus (Capsoni et al., 
2002a). Thus, inspired by the Olabarria’s study, we first verified whether astrocyte atrophy and 
Aβ deposits in AD11 mice do correlate. Then, we formulated the hypothesis whereby astrocytic 
atrophy in AD11 mice is due to deprivation of mature NGF, and thus we analyzed AD11 brain at 
one age (1 month) in which the recombinant antibody is and a second age (2 months) in which 
the transgenic antibody is expressed but  β-amyloid deposits are absent (Capsoni et al., 2002a). 
The age of AD11 mice at which the preliminary observations were obtained is an interesting one, 
because it coincide with the first appearance of Aβ deposits in the hippocampus (Capsoni et al., 
2002a). Thus, inspired by the Olabarria’s study, we first verified whether astrocyte atrophy and 
Aβ deposits in AD11 mice do correlate. Then, we formulated the hypothesis whereby astrocytic 
atrophy in AD11 mice is due to deprivation of mature NGF, and thus we analyzed AD11 brain at 
one age (1 month) in which the recombinant antibody is undetectable (Capsoni et al., 2000) and 
a second age (2 months) in which the transgenic antibody is expressed but  β-amyloid deposits 
are absent (Capsoni et al., 2002a). 
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The number of astrocytes does not change in AD11 mice 
 
Before investigating on the morphological aspects of the diversity between astrocytes from WT 
and AD11 mice, we decided to verify whether the total number of astrocytes per section was 
changed between mutant and WT mice. This was an important data since, as seen before, it 
involves the capability of the astrocytes to interact with neurons and to perform some of their 
functions (such as compartimentalization of the CNS or cerebrovascular regulation) properly. 
We didn’t find a significant difference in the total number of cells (n. of AD11 mice = 3; n.of 
fields in stratum radiatum =  17, n. of fields in  stratum molecularis = 18 ; N. of WT mice = 3; n. 
of fields in stratum radiatum =  17, N. of fields in  stratum molecularis = 18)  (Fig. 15).  
 
Figure 15.  Number of Astrocytes in AD11 and WT mice. Immunohistochemistry for GFAP in the molecular layer of WT 
(A) and AD11 mice (B). Quantification of the number of cells in the (C) stratum radiatum and (B)  molecular layer. Bars 
are representative of mean number of astrocytes/section ± SEM. 
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Astrocyte atrophy and Aβ deposition do not correlate in AD11 mice. 
 
Starting from the findings of Olabarria (Olabarria et al., 2010), who demonstrated a change in 
the glial morphology of 3xTg-AD mice for what concerns surface area, volume and complexity 
of single cells, we checked for similar alterations in astrocytes from AD11 mice. 
For the morphological statistical analysis, outliers were discarded and normality test for single 
parameters was conducted on the samples. Parameters positive for normal distribution were 
compared using t-student test, parameters negative for normality test were compared with 
Freidman and Wilcoxon tests (Table 3). Interestingly, AD11 astrocytes seemed to show in 
general lower p-values for the Shapiro-Wilk normality test, hinting to a more irregular 
distribution of morphometrical values.  
Table 3. Normality tests results 
   
Shapiro-Wilk p-value 
   
WT AD11 
Samples 1 month L 0,341 0,344 
  
A 0,353 0,688 
  
V 0,406 0,384 
  
Bpts 0,348 0,411 
  
Tpts 0,309 0,335 
  
A/V 0,221 0,750 
  
D 0,403 0,765 
 
2 months L 0,466 0,084 
  
A 0,238 0,077 
  
V 0,451 0,082 
  
Bpts 0,324 0,183 
  
Tpts 0,337 0,217 
  
A/V 0,453 0,537 
  
D 0,197 0,600 
 
6 months L 0,684 0,885 
  
A 0,520 0,750 
  
V 0,411 0,236 
  
Bpts 0,602 0,590 
  
Tpts 0,505 0,450 
  
A/V 0,333 0,049 
  
D 0,130 0,077 
 
 
Shapiro-Wilk p-values 
for different parame-
ters of the samples. In 
red the value(s) under 
the significance thre-
shold. 
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First, we examined the level of Aβ deposition associated with the astrocytes in 6 months old 
AD11 mice. As expected from previous observation (Capsoni et al., 2002a), at this age mutant 
mice begin to show Aβ extracellular accumulation that is almost absent in age matched WT mice 
(n. of AD11 mice  = 4; n. of astrocytes in AD11 mice = 16; n of WT mice =  4; n. of astrocytes 
in WT mice = 16., p<0.01). This results are summarized in Fig. 16.  
 
Figura 16  Difference in Aβ deposits volume between AD11 and WT 6 months old mice. On the left, dot plot showing the 
distribution of values for each section. Horizontal line corresponds to the mean value. On the right, bars are 
representative of mean ± SEM. 2-tailed p <0,01. 
  
Subsequently, we analyzed differences between the two groups of animals for what concerns the 
following morphological parameters of AD11 astrocytes: total surface area (A), cellular volume 
(V), total length of the processes (L), complexity (assessed as number of branching points (Brpts) 
and area/volume ratio(A/V)). We found no significant differences in Area (Fig. 17 A,B) or 
Volume (Fig. 17 C,D) between AD11 mice (n. of AD11 mice = 4; n. of astrocytes in AD11 mice 
= 23; n- of WT mice = 4;  n. of astrocytes in WT mice = 23 ). On the contrary, significant 
differences were found  in length (Fig. 5.5 E,F; p<0.05), and very significant differences in 
complexity (Brpts, t-test, p<0.01; A/V, Wilcoxon and Freidman tests , p<0.01) (respectively in 
Fig. 17 G,H and Fig. 17 I,J).  
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Figure 17 (previous page). Graphs showing Dot plots and mean values ± SEM of the different parameters describing 
astrocytic atrophy in AD11 mice. The parameters taken into consideration were (A,B) total surface area, (C,D) cellular 
volume, (E,F) total length of the processes, (G,H) complexity (assessed as number of branching points (Brpts) and (I,J) 
area/volume ratio(A/V)). Dot plots show the values for each astrocytes, while the points in the graph on the right show 
mean ± SEM values. 
 
To verify if the atrophy was caused by the accumulation of Aβ, we plotted values of complexity 
(Brpts) versus the corresponding values of Aβ deposits volume, and performed Pearson and 
Spearman correlation tests. We found no significant correlation between Aβ deposition and 
degree of atrophy (p=0.5773, Fig. 18). This finding was a first piece of evidence against a direct 
role of Aβ in astroglial atrophy. 
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n= 16 
 
Pearson: 
r statistic  -0,15   
 
 
Spearmann: 
rs statistic  -0,15   
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Figure. 18 Correlation analysis performed with Pearson and Spearmann tests revealed no correlation between 
atrophy of astrocytes in AD11 mice and Aβ-expression. 
 
Astroglial atrophy is present in AD11 mice since 2 month of age. 
 
We then hypothesized that astrocyte atrophy was not due to β-amyloid deposition but to NGF 
deprivation. Thus we performed the same analysis conducted on 6 months old mice on 1 and 2 
months old AD11 mice. These ages were chosen because 1) anti-NGF antibody is not detectable 
in 1 month old AD11 mice, 2) at 2 months of age functional anti-NGF antibody is fully 
expressed, 3) Aβ deposition is not observed. 
No significant difference between mutant and WT mice was observed at 1 month (n. of AD11 
mice = 3.; n. of astrocytes in AD11 mice = 12; n- of WT mice = 3;  n. of astrocytes in WT mice = 
12) (Fig. 20). On the other side, at 2 months of age very significant differences (n. of AD11 mice 
= 4.; n. of astrocytes in AD11 mice = 17; n of WT mice = 4;  n. of astrocytes in WT mice = 17, 
p<0.01) were observed in all the parameters of interest (Fig. 20). These results were then 
A
D
1
1
 -
 A
β
 V
o
lu
m
e
 (
µ
m
3
) 
bpts AD11 
Scatter Plot 
58 
 
compared to those obtained from the analysis of 6 month old AD11 mice. We show that the 
differences observed at 2 months of age were more severe than at 6 months of age (Fig 20). We 
concluded that astrocyte atrophy in AD11 mice is absent at 1 month of age, severe at 2 months 
and partially rescued at 6 months of age. 
  
Figure 19 Immunohistochemistry against GFAP in 2 month old WT and AD11 mice. Note the decrease in morphological 
complexity in AD11 mice.  
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Figure 20 Graphs showing Dot plots and mean values ± SEM of the different parameters describing astrocytic atrophy in 
AD11 mice at different ages. The parameters taken into consideration were (A,B) total surface area, (C,D) cellular volume, 
(E,F) total length of the processes, (G,H) complexity (assessed as number of branching points (Brpts) and (I,J) 
area/volume ratio (A/V)). Dot plots show the values for each astrocytes, while the points in the graph on the right show 
mean ± SEM values.  
 
The only deviation from this trend was found when the A/V ratio, which is a parameter of cell 
complexity, was taken in consideration in comparison with another parameter of complexity, the 
number of Branching point. To explain this marked discrepancy, which is particularly evident at 
2 months, we proceeded to the analysis of the mean diameter of the filaments. Thinner and 
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longer ramifications would have caused an higher A/V ratio, but the same number of Bpts.  We 
compared the mean diameter of the filaments at the different ages, and found a very significant 
difference between AD11 and WT mice at 2 and 6 months of age (Fig. 21, p<0.01). Two and 6 
months old AD11 mice showed respectively thinner and thicker filaments, thus explaining the 
discrepancy between the two measures of complexity.  
Analysis within the same genotype among the differente ages showed a significant difference in 
processes diameter between 1 month and 2 months and between 2 months and 6 months in WT 
mice (P < 0.01). On the contrary non significant difference was found among AD11 mice of 
different ages. 
 
 
Figure 21 Graphs showing Dot plots (upper panel) and mean values ± SEM (lower panel) of the diameter in AD11and WT 
mice at different ages. The diameter was significantly reduced at 2 months of age in AD11 mice with respect to age-
matched WT mice. On the contrary, at 6 months of age, the diameter of AD11 mice is larger compared to the one 
measured in WT mice. Dot plots show the values for each astrocytes, while the points in the graph on the right show mean 
± SEM values.  
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Astrocytic atrophy negatively correlates with NGF levels 
 
To verify wheter the morphological features of NGF mice correlated with NGF deprivation, we 
performed ELISA test on samples of blood from 2 months-old AD11 mice (n = 5) and WT mice 
(n = 4) . This age was chosen since at 2 months the difference between mutant and wild type 
astrocytes are more severe. Standard curve for quantifications, shown in Figure 5.10, was made 
as described in Materials and Methods. 
 
Figure 22 Standard curve used to calculate  NGF content in blood serum from WT and AD11 mice.  
 
As expected (Ruberti et al., 2000) NGF levels in the blood serum of AD11 mice was 
significantly lower (P < 0.01) with respect to WT mice (Fig. 23) 
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Figure 23 At 2 months of age, NGF levels are decreased in the blood serum of AD11 mice with respect to age-matched WT 
mice. Bars are representative of mean ± SEM. 
 
NGF plasmatic levels of AD11 mice were then tested for normality (p=0.253) and plotted versus 
some morphological parameters (Area, Volume, Length, complexity (Bpts); Fig. 24). Linearity 
test was performed and Pearson correlation coefficient were then calculated. 
NGF levels in 2 months old mice correlates with all the analyzed parameters, hinting at a precise 
role of NGF in determining astrocyte morphology. 
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Figure 24 The graphs show a positive correlation between the decrease in NGF content in the blood serum and 
morphological alterations in astrocytes of AD11 mice.  
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Atrophic astrocytes are not immature cells.  
 
To exclude the possibility of the observed astroglial atrophy being due to simple immaturity of 
the analyzed cells, we used anti-vimentin immunostaining on 2 month old mice. As it was 
described before (Table 1) vimentin is a marker of astrocytic immaturity and it is replaced, as 
most abundant intermediate filament, by GFAP at later ages. We found that in WT mice at 2 
months of age vimentin is mainly expressed in blood vessels of the stratum molecularis (Fig. 25), 
as expected (Franke et al., 1979). Similarly in age matched AD11 mice we did not found 
vimentin immunoreactive astrocyts, but only blood vessels. Thus we concluded that NGF 
deprivation did not completely block maturation of astrocytes in AD11 mice. 
 
Figure 25. At 2 month of age, the anti-vimentin antibody labels only blood vessels in both WT and AD11 mice.  
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Discussion 
 
In this study, we found that NGF deprivation provokes an atrophy of GFAP-immunoreactive 
astrocytes in 2 month-old AD11 mice and that this atrophy decreases in older, 6 month-old 
transgenic mice. In addition, we show that, contrary to another mouse model for AD, the 3xTg-
AD mice (Olabarria et al., 2010), Aβ expression seems not correlate with astrocytic atrophy. 
As reported in the Introduction to this Thesis, NGF has been studied in terms of its production 
from cultured astrocytes and in relation to cell proliferation. Only a few studies addressed the 
effects of NGF on astrocyte morphology, showing that NGF deprivation induces a switch from a 
flat polygonal cell to flat fibroblast-like structure (Hutton and Perez-Polo, 1995). However, this 
study was performed in cultured astrocytes, which do not assume the classical ramified 
morphology that is shown by these cells in vivo.  
Different questions arise from this study. First of all, why beta amyloid expression does not 
correlate with astrocytic atrophy? Secondly, how our findings reconcile with the maturation 
processes to which astrocytes undergo during the rodent life? Third, due to the heterogeneity of 
astrocytes, particularly in the hippocampal area, is NGF deprivation selecting a specific subset of 
astrocytes? How can NGF deprivation induce a decrease in astrocyte morphological complexity? 
What can be the consequences of this alteration in morphology on astrocyte functions in the 
brain?  
About the first question, we observed that astrocytic atrophy in AD11 mice is more severe at 2 
months, an age during which Aβ is not expressed, and milder when Aβ deposits appear. Reports 
on the effect of Aβ on astrocytes are conflicting. On one hand, Aβ is reported to be toxic for 
cultured embryonic astrocytes (Assis-Nascimento et al., 2007). On the other hand, in cultured 
hippocampal astrocytes, it was found that Aβ increases NGF production (Saez et al., 2006; 
Schulte-Herbruggen et al., 2007); and per se induces branching of astrocytes (Jalonen et al., 
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1997). 
Thus, it cannot be excluded that a local production of NGF might compensate the atrophy 
induced by the anti-NGF antibody though an autocrine loop due to the known expression of 
TrkA receptor on hippocampal astrocytes (Hutton et al., 1992).  
For what concerns the second question, the data described in this Thesis show a precise time of 
onset (2 months of age) of the effects of NGF deprivation, which we demonstrated to be due to 
the decrease in the levels of  NGF not neutralized by the recombinant αD11 antibody and free to 
bind to NGF receptors.  
In rat Ammon’s horn, the number of GFAP-immunoreactive astrocytes increases by postnatal 
day 16 (Nixdorf-Bergweiler et al., 1994). By the end of the first week of age, astrocytes assume 
the classical stellate morphology (Woodhams et al., 1981). These studies were based on the 
analysis of the  maturation of GFAP-immunoreactive astrocytes (Nixdorf-Bergweiler et al., 1994; 
Catalani et al., 2002), showing that this cytoskeletal protein progressively elongates and ramifies 
in astrocytes during the first postnatal month and then declines in volume and branches until 
stabilization that occurs around 5 months of age (Catalani et al., 2002). Our data obtained in WT 
mice show a similar trend: the ratio between astrocytic area and volume decreases from 1 to 2 
months of age and then start to increase again at 6 month of age.  On the contrary, in AD11 mice 
we show an opposite showing that from 2 months of age, corresponding to the beginning of NGF 
deprivation, until 6 months of age the A/V ratio decreases. These data prompted to the fact that 
NGF deprivation provokes a blockade of astrocyte maturation.  
In mice, vimentin expression in astrocytes decreases during the first three postnatal weeks   
(Sancho-Tello et al., 1995). The fact that immature vimentin-positive astrocytes are absent not 
only in WT mice, but also in AD11 mice suggest that the maturation of astrocytes should be 
normal in AD11 until the beginning of  NGF neutralization.  Thus, the altered morphology of 
GFAP-immunoreactive astrocytes in these transgenic mice is not due to the mere expression of 
the recombinant antibody, but it is specifically linked to the decreased activity of the 
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neurotrophin. 
Beside the hypothesis that NGF deprivation might induce a blockade of the maturation of 
astrocytes, we cannot exclude an effect on the processes that induce heterogeneity in the 
population of GFAP-positive astrocytes. In particular, in the hippocampus, two populations of 
GFAP-immunoreactive astrocytes have been reported to have a distinct morphology.  In one case 
the cells resemble classical protoplasmic astrocytes with expanded, branched nets of processes. 
The second population is characterized, similarly to the astrocytes shown in 2 month-old AD11 
mice, by shorter and thinner process (Matthias et al., 2003). These two types of astrocytes are 
functionally distinct since they express, respectively, glutamate transporters and AMPA-type 
glutamate receptors (Matthias et al., 2003). The latter is also characterized by the complete lack 
of gap junction coupling with other astrocytes, and its physiological function is still to be defined 
(Wallraff et al., 2004). In addition, it is still not clear whether these two different types of 
astrocytes represent two distinct populations (Matthias et al., 2003) or a different functional state 
of the same (Verkhratsky and Steinhauser, 2000). Thus, we cannot exclude that NGF deprivation 
can affect the heterogeneity of astrocyte population, either by the selection of a single population 
of astrocytes or by induction of a more homogenous functional state of these cells.  
Protoplasmic astrocyte complexity is primarily due to the high degree of ramification of the cell 
processes. NGF deprivation in AD11 mice induces a minor degree of branching. We still do not 
know how the decrease in the activity of NGF can affect the morphology of astrocyte processes, 
but some hypothesis can be formulated on the basis of previous studies. The process that leads to 
the ramification of astrocytes has been extensively studied in vitro, and named “stellation”. This 
part of astrocyte maturation can be affected by various molecules, with can in turn be affected by 
alterations in NGF signalling.  
Indeed, NGF might act in synergy or induce the synthesis of  other factors that induce astrocyte 
stellation: Since many of these factors, for example laminin (Gottfried et al., 2003) actin or  
myosin, function in a similar way as in mechanism related to nerve sprouting (Burgos et al., 
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2007), it cannot be excluded that  also NGF can function in astrocytes as in neurons. However, 
experimental evidence for this should be obtained. 
 For what concern the consequences of the decreased morphological complexity of astrocytes in 
AD11 mice, we can hypothesize that some of the functions played by these cells should be 
impaired. 
First of all, astrocytes control the integrity of the blood brain barrier and cerebral blood flow by 
surrounding, with their perivascular end-feet all parts of the vasculature (Zonta et al., 2003b; 
Zlokovic, 2008). This means that, if astrocyte processes cannot reach the wall of blood vessels, 
the blood brain barrier integrity will be compromised. This data is in line with the finding of an 
increased permeability of the blood brain barrier in anti-NGF mice (Capsoni et al., 2010a).  
Most importantly, processes of astrocytes wall off groups of neurons and their synapses. Indeed,  
Individual astrocytes form virtually non-overlapping domains (Bushong et al., 2002).  The highly 
branched processes of astrocytes are interconnected by gap junctions, which facilitate calcium 
signaling within the cell and between 
neighboring astrocytes (Giaume et al., 2010). Retraction of the enwrapping of neurons and 
synapses might increase the interaction between neurons and disrupt the regular flow of calcium 
signaling. Interestingly, signiﬁcant changes have recently been discovered in astrocyte networks 
and their calcium signaling patterns in AD mice (Kuchibhotla et al., 2009; Peters et al., 2009). 
Envelopment of synapses facilitates neuronal activity and withdrawal facilitates suppression of 
inappropriate activity (Genoud et al., 2006; Haber et al., 2006; Panatier et al., 2011), thus a 
contribution of astrocyte atrophy to the alterations in neuronal activity might be expected also in 
AD11 mice.  
In conclusion, this study adds new information about the neurodegenerative phenotype in AD11 
mice and the role played by NGF in the regulation of astrocyte morphology in vivo. Since little 
is known about signaling pathways that direct the specification and morphogenesis of astrocytes 
(Freeman, 2010),  this study contributes also in the attempt to better understand the heterogeneity 
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of astrocytes and their function in normal brain and in neurodegenerative diseases. Further 
studies are required to better characterize from the molecular and functional point of view 
atrophic astrocytes in anti-NGF and correlate it to neurodegenerative disorders.  
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